223 related articles for article (PubMed ID: 31235532)
1. TransCon CNP, a Sustained-Release C-Type Natriuretic Peptide Prodrug, a Potentially Safe and Efficacious New Therapeutic Modality for the Treatment of Comorbidities Associated with Fibroblast Growth Factor Receptor 3-Related Skeletal Dysplasias.
Breinholt VM; Rasmussen CE; Mygind PH; Kjelgaard-Hansen M; Faltinger F; Bernhard A; Zettler J; Hersel U
J Pharmacol Exp Ther; 2019 Sep; 370(3):459-471. PubMed ID: 31235532
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamics results of a long-acting C-type natriuretic peptide prodrug, TransCon CNP.
Breinholt VM; Mygind PH; Christoffersen ED; Zhang Y; Ota S; Will Charlton R; Viuff D
Br J Clin Pharmacol; 2022 Nov; 88(11):4763-4772. PubMed ID: 35481707
[TBL] [Abstract][Full Text] [Related]
3. Neutral endopeptidase-resistant C-type natriuretic peptide variant represents a new therapeutic approach for treatment of fibroblast growth factor receptor 3-related dwarfism.
Wendt DJ; Dvorak-Ewell M; Bullens S; Lorget F; Bell SM; Peng J; Castillo S; Aoyagi-Scharber M; O'Neill CA; Krejci P; Wilcox WR; Rimoin DL; Bunting S
J Pharmacol Exp Ther; 2015 Apr; 353(1):132-49. PubMed ID: 25650377
[TBL] [Abstract][Full Text] [Related]
4. A long-acting C-natriuretic peptide for achondroplasia.
Schneider EL; Carreras CW; Reid R; Ashley GW; Santi DV
Proc Natl Acad Sci U S A; 2022 Jul; 119(30):e2201067119. PubMed ID: 35858423
[TBL] [Abstract][Full Text] [Related]
5. Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trial.
Savarirayan R; Hoernschemeyer DG; Ljungberg M; Zarate YA; Bacino CA; Bober MB; Legare JM; Högler W; Quattrin T; Abuzzahab MJ; Hofman PL; White KK; Ma NS; Schnabel D; Sousa SB; Mao M; Smith A; Chakraborty M; Giwa A; Winding B; Volck B; Shu AD; McDonnell C
EClinicalMedicine; 2023 Nov; 65():102258. PubMed ID: 37823031
[TBL] [Abstract][Full Text] [Related]
6. Evidence of feedback regulation of C-type natriuretic peptide during Vosoritide therapy in Achondroplasia.
Prickett TCR; Espiner EA; Irving M; Bacino C; Phillips JA; Savarirayan R; Day JRS; Fisheleva E; Larimore K; Chan ML; Jeha GS
Sci Rep; 2021 Dec; 11(1):24278. PubMed ID: 34930956
[TBL] [Abstract][Full Text] [Related]
7. Design and Preclinical Development of TransCon PTH, an Investigational Sustained-Release PTH Replacement Therapy for Hypoparathyroidism.
Holten-Andersen L; Pihl S; Rasmussen CE; Zettler J; Maitro G; Baron J; Heinig S; Hoffmann E; Wegge T; Krusch M; Faltinger F; Killian S; Sprogoe K; Karpf DB; Breinholt VM; Cleemann F
J Bone Miner Res; 2019 Nov; 34(11):2075-2086. PubMed ID: 31291476
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway.
Yasoda A; Komatsu Y; Chusho H; Miyazawa T; Ozasa A; Miura M; Kurihara T; Rogi T; Tanaka S; Suda M; Tamura N; Ogawa Y; Nakao K
Nat Med; 2004 Jan; 10(1):80-6. PubMed ID: 14702637
[TBL] [Abstract][Full Text] [Related]
9. Vosoritide: First Approval.
Duggan S
Drugs; 2021 Nov; 81(17):2057-2062. PubMed ID: 34694597
[TBL] [Abstract][Full Text] [Related]
10. Chronically elevated plasma C-type natriuretic peptide level stimulates skeletal growth in transgenic mice.
Kake T; Kitamura H; Adachi Y; Yoshioka T; Watanabe T; Matsushita H; Fujii T; Kondo E; Tachibe T; Kawase Y; Jishage K; Yasoda A; Mukoyama M; Nakao K
Am J Physiol Endocrinol Metab; 2009 Dec; 297(6):E1339-48. PubMed ID: 19808910
[TBL] [Abstract][Full Text] [Related]
11. ASB20123: A novel C-type natriuretic peptide derivative for treatment of growth failure and dwarfism.
Morozumi N; Yotsumoto T; Yamaki A; Yoshikiyo K; Yoshida S; Nakamura R; Jindo T; Furuya M; Maeda H; Minamitake Y; Kangawa K
PLoS One; 2019; 14(2):e0212680. PubMed ID: 30794654
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of vosoritide in the treatment of achondroplasia.
Paton DM
Drugs Today (Barc); 2022 Sep; 58(9):451-456. PubMed ID: 36102905
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia.
Lorget F; Kaci N; Peng J; Benoist-Lasselin C; Mugniery E; Oppeneer T; Wendt DJ; Bell SM; Bullens S; Bunting S; Tsuruda LS; O'Neill CA; Di Rocco F; Munnich A; Legeai-Mallet L
Am J Hum Genet; 2012 Dec; 91(6):1108-14. PubMed ID: 23200862
[TBL] [Abstract][Full Text] [Related]
14. [Genetic basis for skeletal disease. CNP therapy for achondroplasia].
Yasoda A; Nakao K
Clin Calcium; 2010 Aug; 20(8):1212-8. PubMed ID: 20675932
[TBL] [Abstract][Full Text] [Related]
15. Circulatory CNP Rescues Craniofacial Hypoplasia in Achondroplasia.
Yamanaka S; Nakao K; Koyama N; Isobe Y; Ueda Y; Kanai Y; Kondo E; Fujii T; Miura M; Yasoda A; Nakao K; Bessho K
J Dent Res; 2017 Dec; 96(13):1526-1534. PubMed ID: 28644737
[TBL] [Abstract][Full Text] [Related]
16. C-type natriuretic peptide plasma levels are elevated in subjects with achondroplasia, hypochondroplasia, and thanatophoric dysplasia.
Olney RC; Prickett TC; Espiner EA; Mackenzie WG; Duker AL; Ditro C; Zabel B; Hasegawa T; Kitoh H; Aylsworth AS; Bober MB
J Clin Endocrinol Metab; 2015 Feb; 100(2):E355-9. PubMed ID: 25387261
[TBL] [Abstract][Full Text] [Related]
17. C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia.
Savarirayan R; Irving M; Bacino CA; Bostwick B; Charrow J; Cormier-Daire V; Le Quan Sang KH; Dickson P; Harmatz P; Phillips J; Owen N; Cherukuri A; Jayaram K; Jeha GS; Larimore K; Chan ML; Huntsman Labed A; Day J; Hoover-Fong J
N Engl J Med; 2019 Jul; 381(1):25-35. PubMed ID: 31269546
[TBL] [Abstract][Full Text] [Related]
18. Foramen magnum stenosis and midface hypoplasia in C-type natriuretic peptide-deficient rats and restoration by the administration of human C-type natriuretic peptide with 53 amino acids.
Yotsumoto T; Morozumi N; Furuya M; Fujii T; Hirota K; Ueda Y; Nakao K; Yamanaka S; Yoshikiyo K; Yoshida S; Nishimura T; Abe Y; Jindo T; Ogasawara H; Yasoda A
PLoS One; 2019; 14(5):e0216340. PubMed ID: 31120905
[TBL] [Abstract][Full Text] [Related]
19. Systemic administration of C-type natriuretic peptide as a novel therapeutic strategy for skeletal dysplasias.
Yasoda A; Kitamura H; Fujii T; Kondo E; Murao N; Miura M; Kanamoto N; Komatsu Y; Arai H; Nakao K
Endocrinology; 2009 Jul; 150(7):3138-44. PubMed ID: 19282381
[TBL] [Abstract][Full Text] [Related]
20. Translational research of C-type natriuretic peptide (CNP) into skeletal dysplasias.
Yasoda A; Nakao K
Endocr J; 2010; 57(8):659-66. PubMed ID: 20567091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
